It is obtained from isolation from a bacteria. It is an aminoglycoside bacteriocidal antibiotic. It kills the bacteria by stopping the production of essential proteins needed by the bacteria to survive. Kanamycin may be considered as initial therapy in the treatment of infections where E. coli, Proteus species (both indole-positive and indole-negative), Enterobacter aerogenes, Klebsiella pneumoniae, Serratia marcescens, Acinetobacter are the pathogens.
Related Journals of Kanamycin
Advances in Antibiotics & Antibodies:Clinical Journal JournalsGenetics & Molecular Biology JournalsHealth Care Journal JournalsImmunology & Microbiology Journal JournalsMedical Journal Journals, Monoclonal Antibodies in Immunodiagnosis and Immunotherapy, Human Antibodies, Clinical Microbiology: Open Access
